Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Anticd20 Monoclonal Antibody

Research Leaders

5 sponsors active, led by Yale University

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05286242Completed

Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients

NCT06711354Unknown

B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment

Showing all 2 trials

Research Network

Common Treatments

  • Anticd20 Monoclonal Antibody1
  • Covid19 Vaccine1

Active Sponsors

  • Yale University1
  • Region Stockholm1
  • Haukeland University Hospital1
  • National Institute of Allergy and Infectious Diseases (NIAID)1
  • Robert Leet and Clara Guthrie Patterson Trust1

Top Investigators

Related Conditions

  • Multiple Sclerosis2
  • Immunosuppression1
  • Offspring Adult1
  • Autoimmune Blistering Disease1
  • Pregnancy Related1

Activity Timeline